The Herbal Drug, Polysaccharide K, has an Immunological and Synergistic Anticancer Effect with Cetuximab for Gastrointestinal Cancer in Vivo
Keywords:
Abstract
Cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, has been widely used for therapy of several kinds of malignant diseases. However, the anticancer effect is incomplete. The purpose of this study was to examine the synergism between the herbal drug, Polysaccharide K, and Cetuximab against gastrointestinal cancer cell lines in vitro and in vivo. Two gastrointestinal cancer cell lines positive for EGFR expression were used for this study. In the in vivo study, mice were xenografted with cancer cell lines subcutaneously. Neither PSK nor Cetuximab suppressed cell proliferation. However, when both drugs were administered, cancer growth was suppressed significantly compared with treatment with Cetuximab alone. This study demonstrated that PSK has the potential to enhance Cetuximab's effect on gastrointestinal cancer.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
H. Lu (2011) TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy. 17(21), 6742-6753. https://doi.org/10.1158/1078-0432.ccr-11-1142
S. Ohwada (2004) Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. 90(6), 1003-. https://doi.org/10.1038/sj.bjc.6602101
(2006) CALGB/SWOG C80405: A phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum. 4, 452-453.
S. Politano (2008) Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. 7(1), 55-59. https://doi.org/10.3816/ccc.2008.n.008
Nicolas Moosmann, Volker Heinemann (2008) Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. 8(3), 319-329. https://doi.org/10.1586/14737140.8.3.319
Shelby Terstriep, Axel Grothey (2006) First- and second-line therapy of metastatic colorectal cancer. 6(6), 921-930. https://doi.org/10.1586/14737140.6.6.921
M. Saif (2009) Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. 65(1), 107-112. https://doi.org/10.1007/s00280-009-1009-6
Muhammad Saif, J. Peccerillo, Von Potter (2009) Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. 63(6), 1017-1022. https://doi.org/10.1007/s00280-008-0831-6
Eric Van Cutsem (2006) Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer. 11(9), 1010-1017. https://doi.org/10.1634/theoncologist.11-9-1010
M. Hara (2008) Interleukin‐2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor‐overexpressing gastric cancer xenografts through antibody‐dependent cellular cytotoxicity. 99(7), 1471-1478. https://doi.org/10.1111/j.1349-7006.2008.00821.x
A. Rosendahl, C. Sun, D. Wu, R. Andersson Polysaccharide-K (PSK) increases p21(WAF/Cip1) and promotes apoptosis in pancreatic cancer cells.
Published
2013-07-01
Issue
Section
License
Copyright (c) 2013 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.